论文部分内容阅读
Chemoradiation based on cisplatin is the standard treatment for locally advanc ed cervical carcinoma; however, the optimal scheduling and dosing have still not been established. This study was conducted to determine the maximum-tolerated dose (MTD) of cisplatin for daily administration during pelvic radiotherapy (RT) . Fourteen patients with locally advanced cervical carcinoma and 13 who required postoperative RT were registered. A low dose of cisplatin was given daily concu rrently with RT. Cisplatin dosing was started at 6.0 mg/m2/day, which was increm ented by 0.5 mg/m2/day. RT was delivered at 2 Gy/day to a total dose of 50 Gy. T he MTD was defined as the dose level immediately below that causing dose-limiti ng toxicity (DLT) in over one-third of treated patients. Twentyfive patients we re treated with a maximum of six escalating dose levels. In 22/25 patients (88% ), cisplatin was administered continuously as planned without interruption. The MTD was determined to be 8 mg/m2 and the DLT was indicated by the onset of neutr openia. Daily cisplatin, at 8 mg/m2/day, is a well-tolerated radiosensitizer in cervical carcinoma patients.
Chemoradiation based on cisplatin is the standard treatment for locally advanc ed cervical carcinoma; however, the optimal scheduling and dosing have still not been established. This study was conducted to determine the maximum-tolerated dose (MTD) of cisplatin for daily administration during pelvic radiotherapy (RT). Fourteen patients with locally advanced cervical carcinoma and 13 who required postoperative RT were registered. A low dose of cisplatin was given daily concurent with RT. Cisplatin dosing was started at 6.0 mg / m2 / day, which was incremted by 0.5 mg / m2 / day. RT was delivered at 2 Gy / day to a total dose of 50 Gy. T he MTD was defined as the dose level immediately below that causing dose-limiti ng toxicity (DLT) in over one-third of treated patients. Twentyfive patients we re treated with a maximum of six escalating dose levels. In 22/25 patients (88%), cisplatin was administered continuously planned without interruption. The MTD was determined to be 8 mg / m2 and t he DLT was indicated by the onset of neutr openia. Daily cisplatin, at 8 mg / m2 / day, is a well-tolerated radiosensitizer in cervical carcinoma patients.